Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?!
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?!
Authors
Keywords
Targeted treatment, VEGF, EGFR, Palliative treatment, Colorectal cancer
Journal
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume 141, Issue 3, Pages 515-522
Publisher
Springer Nature
Online
2014-09-18
DOI
10.1007/s00432-014-1829-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial
- (2014) E Samalin et al. BRITISH JOURNAL OF CANCER
- A phase 1 trial of imatinib, bevacizumab and metronomic cyclophosphamide in advanced colorectal cancer
- (2013) R K Kelley et al. BRITISH JOURNAL OF CANCER
- Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
- (2012) Jaafar Bennouna et al. LANCET ONCOLOGY
- Safety and Pharmacokinetics of Sorafenib Combined With Capecitabine in Patients With Advanced Solid Tumors: Results of a Phase 1 Trial
- (2011) Ahmad Awada et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Therapeutic strategy in unresectable metastatic colorectal cancer
- (2011) Benoist Chibaudel et al. Therapeutic Advances in Medical Oncology
- Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer
- (2010) Camilla Qvortrup et al. ACTA ONCOLOGICA
- Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study
- (2010) M. Moehler et al. ANNALS OF ONCOLOGY
- Colorectal cancer: response to sunitinib in a heavily pretreated colorectal cancer patient
- (2010) Joan Manel Gasent Blesa et al. ANTI-CANCER DRUGS
- Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
- (2010) Marc Peeters et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase II Study of Gefitinib, 5-Fluorouracil, Leucovorin, and Oxaliplatin in Previously Untreated Patients with Metastatic Colorectal Cancer
- (2008) G. A. Fisher et al. CLINICAL CANCER RESEARCH
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
- (2008) Leonard B. Saltz et al. JOURNAL OF CLINICAL ONCOLOGY
- EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer
- (2008) Alberto F. Sobrero et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started